TACE联合索拉非尼治疗原发性肝癌的研究进展
Research Progress of TACE Combined with Sorafenib in the Treatment of HCC

DOI: 10.12677/ACRPO.2020.94004, PP. 17-21

Keywords: 原发性肝癌，HCC，肝动脉化疗栓塞术，TACE，索拉非尼
Hepatocellular Carcinoma, HCC, Hepatic Artery Chemoembolization, TACE, Sorafenib

Full-Text   Cite this paper   Add to My Lib

Abstract:

原发性肝癌(Hepatocellular carcinoma, HCC)起病隐匿，虽然手术治疗是首选，但患者因出现临床症状而就医时大多已进入中晚期，选择单纯的手术治疗不能达到预期的目的。针对这部分患者，肝动脉化疗栓塞术(transcatheter arterial chemoembolization, TACE)已成为首选。然而，采用此治疗方式，虽然能一定程度上缓解病情，但治疗效果有限。多项研究表明采用TACE联合索拉非尼的治疗方法，可以使中晚期原发性肝癌患者获益颇多，本文参考相关资料，探讨TACE联合索拉非尼治疗原发性肝癌的相关研究进展。
Hepatocellular carcinoma (HCC) has an insidious onset. Although surgical treatment is the first choice, most of the patients have entered the middle and advanced stages when they seek medical attention due to clinical symptoms, and surgical treatment alone cannot achieve the expected goals. For these patients, transcatheter arterial chemoembolization (TACE) has become the first choice. Although this treatment method can relieve the condition to a certain extent, the treatment effect is limited. A number of studies have shown that the use of TACE combined with sorafenib can benefit patients with advanced Hepatocellular carcinoma. This article refers to related materials to discuss the research progress of TACE combined with sorafenib in the treatment of Hepatocellular carcinoma.

References

[1]	刘文东. 原发性肝癌诊疗进展[J]. 中西医结合心血管病电子杂志, 2018, 6(31): 162-163.
[2]	黄成, 孙惠川. 《原发性肝癌诊疗规范(2019年版)》肝脏外科领域更新的展望[J]. 外科理论与实践, 2020, 25(1): 6-9.
[3]	Han, K. and Kim, J.H. (2015) Transarterial Chemoembolization in Hepatocellular Carcinoma Treatment: Barcelona Clinic Liver Cancer Staging System. World Journal of Gastroenterology, 21, 10327-10335. https://doi.org/10.3748/wjg.v21.i36.10327
[4]	Chang, L., Wang, Y., Zhang, J., et al. (2017) The Best Strategy for HCC Patients at Each BCLC Stage: A Network Meta-Analysis of Observational Studies. Oncotarget, 8, 20418-20427. https://doi.org/10.18632/oncotarget.14668
[5]	闫东. 2018《CSCO原发性肝癌诊疗指南》解读——肝动脉介入治疗部分[J]. 肝癌电子杂志, 2018, 5(3): 4-7.
[6]	Ogasawara, S., Ooka, Y., Koroki, K., et al. (2020) Switching to Systemic Therapy after Locoregional Treatment Failure: Definition and Best Timing. Clinical and Molecular Hepatology, 26, 155-162. https://doi.org/10.3350/cmh.2019.0021n
[7]	Li, L., Zhao, W., Wang, M., et al. (2018) Transarterial Chemoembo-lization plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review and Me-ta-Analysis. BMC Gastroenterology, 18, 138. https://doi.org/10.1186/s12876-018-0849-0
[8]	Raoul, J.L., Forner, A., Bolondi, L., Cheung, T.T., Kloeckner, R. and de Baere, T. (2019) Updated Use of TACE for Hepatocellular Carcinoma Treatment: How and When to Use It Based on Clinical Evidence. Cancer Treatment Reviews, 72, 28-36. https://doi.org/10.1016/j.ctrv.2018.11.002
[9]	Lencioni, R., Petruzzi, P. and Crocetti, L. (2013) Chemoemboliza-tion of Hepatocellular Carcinoma. Seminars in Interventional Radiology, 30, 3-11. https://doi.org/10.1055/s-0033-1333648
[10]	王瑞航, 姚升娟, 张晨, 等. 肝动脉化疗栓塞介入术对原发性肝癌患者近期疗效及Child-Pugh分级的影响[J]. 医学信息, 2020, 33(17): 101-102.
[11]	Zhao, M., Xiang, P. and Jiang, H. (2018) TransArterial ChemoEmbolization (TACE) with Platinum versus Anthracyclines for Hepatocellular Carcinoma: A Meta-Analysis. International Journal of Surgery, 53, 151-158. https://doi.org/10.1016/j.ijsu.2018.03.049
[12]	Abdelgalil, A.A., Alkahtani, H.M. and Al-Jenoobi, F.I. (2019) So-rafenib. In: Profiles of Drug Substances, Excipients, and Related Methodology, Vol. 44, Elsevier, Amsterdam, 239-266. https://doi.org/10.1016/bs.podrm.2018.11.003
[13]	Leal, C.R.G., Magalh？es, C., Barbosa, D., et al. (2018) Surviv-al and Tolerance to Sorafenib in Child-Pugh B Patients with Hepatocellular Carcinoma: A Prospective Study. Investiga-tional New Drugs, 36, 911-918. https://doi.org/10.1007/s10637-018-0621-x
[14]	Ziogas, D.C., Papadatos-Pastos, D., Thillai, K., et al. (2017) Effi-cacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Age Is Not a Problem. European Journal of Gastroenterology & Hepatology, 29, 48-55. https://doi.org/10.1097/MEG.0000000000000739
[15]	Zhuang, B.W., Li, W., Xie, X.H., et al. (2019) Sorafenib versus Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Systematic Review and Me-ta-Analysis. Japanese Journal of Clinical Oncology, 49, 845-855. https://doi.org/10.1093/jjco/hyz069
[16]	Zhang, X., Wang, K., Wang, M., et al. (2017) Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Oncotarget, 8, 29416-29427. https://doi.org/10.18632/oncotarget.15075
[17]	Yuan, J., Yin, X., Tang, B., et al. (2019) Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study. BioMed Research International, 2019, Article ID: 2141859. https://doi.org/10.1155/2019/2141859
[18]	Huang, Y., Chen, B., Liu, N., et al. (2017) Overall Survival in Response to Sorafenib with Transarterial Chemoembolization for BCLC Stage B Hepatocellular Car-cinoma: Propensity Score Analysis. International Journal of Clinical Pharmacology and Therapeutics, 55, 498-508. https://doi.org/10.5414/CP202787
[19]	Kok, V.C., Chen, Y.C., Chen, Y.Y., et al. (2019) Sorafenib with Transarte-rial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Na-tionwide Population-Based Cohort Study. Cancers (Basel), 11, 985. https://doi.org/10.3390/cancers11070985
[20]	Feng, F., Jiang, Q., Jia, H., et al. (2018) Which Is the Best Combi-nation of TACE and Sorafenib for Advanced Hepatocellular Carcinoma Treatment? A Systematic Review and Network Meta-Analysis. Pharmacological Research, 135, 89-101. https://doi.org/10.1016/j.phrs.2018.06.021

Full-Text